rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2025-443-451rsp-3804Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESБолезнь Шёгрена: мифы и реальность. Часть IISjogren’s disease: myths and reality. Part IIhttps://orcid.org/0000-0003-4188-3578ЧальцевБ. Д.ChaltsevB. D.

Чальцев Богдан Дмитриевич 

115522, Москва, Каширское шоссе, 34а

Bogdan D. Chaltsev 

115522, Moscow, Kashirskoye Highway, 34A

bodya92@inbox.ruhttps://orcid.org/0000-0002-1425-8622ВасильевВ. И.VasilyevV. I.

107140, Москва, ул. Нижняя Красносельская, 4

Vladimir I. Vasilyev 

107140, Moscow, Nizhnyaya Krasnoselskaya str., 4

https://orcid.org/0000-0001-8099-2107ТоргашинаА. В.TorgashinaA. V.

115522, Москва, Каширское шоссе, 34а

Anna V. Torgashina 

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationООО «Ревмоцентр»Россия“Revmotsentr” LLCRussian Federation202501112025635443451Copyright © Чальцев Б.Д., Васильев В.И., Торгашина А.В., 20252025Чальцев Б.Д., Васильев В.И., Торгашина А.В.Chaltsev B.D., Vasilyev V.I., Torgashina A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3804

Стоматологические и офтальмологические проявления болезни Шёгрена (БШ) впервые описаны более 100 лет назад, а в качестве самостоятельной нозологической единицы БШ получила признание в 1965 году. Тем не менее в настоящее время диагностика и лечение данного заболевания по-прежнему вызывают существенные затруднения. Во второй части статьи приведены наиболее распространенные и значимые мифы о клинических и лабораторных проявлениях, лимфопролиферативных осложнениях, а также о лечении БШ.

Oral and ocular manifestations of Sjögren’s disease (SjD) were first described over 100 years ago, but SjD was recognized as an independent nosology in 1965. However, currently the diagnosis and treatment of this disease still pose significant difficulties. The second part of the article presents the most common and significant myths in clinical and laboratory manifestations, lymphoproliferative complications, and treatment of SjD.

болезнь Шёгренасиндром ШёгренаMALT-лимфомакриоглобулинемияваскулитритуксимабSjogren’s diseaseSjogren’s syndromeMALT lymphomacryoglobulinemiavasculitisrituximabСтатья подготовлена в рамках фундаментальной темы, регистрационный № 1021051402790-6.ReferencesVivino FB, Bunya VY, Massaro-Giordano G, Johr CR, Giattino SL, Schorpion A, et al. Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019;203:81-121. doi: 10.1016/j.clim.2019.04.009Vivino FB, Bunya VY, Massaro-Giordano G, Johr CR, Giattino SL, Schorpion A, et al. Sjogren’s syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019;203:81-121. doi: 10.1016/j.clim.2019.04.009Ramos-Casals M, Acar-Denizli N, Vissink A, Brito-Zerón P, Li X, Carubbi F, et al.; Sjogren Big Data Consortium. Childhoodonset of primary Sjögren’s syndrome: Phenotypic characterization at diagnosis of 158 children. Rheumatology (Oxford). 2021;60(10):4558-4567. doi: 10.1093/rheumatology/keab032Ramos-Casals M, Acar-Denizli N, Vissink A, Brito-Zerón P, Li X, Carubbi F, et al.; Sjogren Big Data Consortium. Childhoodonset of primary Sjögren’s syndrome: Phenotypic characterization at diagnosis of 158 children. Rheumatology (Oxford). 2021;60(10):4558-4567. doi: 10.1093/rheumatology/keab032Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015;11(5):301-312. doi: 10.1038/nrrheum.2015.29Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015;11(5):301-312. doi: 10.1038/nrrheum.2015.29Сафонова ТН, Васильев ВИ, Лихванцева ВГ. Синдром Шегрена: Руководство для врачей. М.:Издательство Московского государственного университета;2013.Safonova TN, Vasiliev VI, Likhvantseva VG. Sjögren‘s syndrome: A guide for physicians. Moscow:Publishing House of Moscow State University;2013 (In Russ.).Tsampoulas CG, Skopouli FN, Sartoris DJ, Kaplan P, Kursunoglu S, Pineda C, et al. Hand radiographic changes in patients with primary and secondary Sjögren’s syndrome. Scand J Rheumatol. 1986;15(3):333-339. doi: 10.3109/03009748609092600Tsampoulas CG, Skopouli FN, Sartoris DJ, Kaplan P, Kursunoglu S, Pineda C, et al. Hand radiographic changes in patients with primary and secondary Sjögren’s syndrome. Scand J Rheumatol. 1986;15(3):333-339. doi: 10.3109/03009748609092600Васильев ВИ, Симонова МВ, Сафонова ТН, Мач ЭС. Сравнительная оценка эффективности лечения синдрома Шегрена противоревматическими препаратами. Терапевтический архив. 1988;60(4):67-72.Vasil’ev VI, Simonova MV, Safonova TN, Mach ES. Comparative evaluation of the treatment of Sjögren’s syndrome with anti-rheumatic preparations. Terapevticheskii arkhiv. 1988;60(4):67-72 (In Russ.).Шорникова НС, Васильев ВИ, Смирнов АВ. Поражение суставов при болезни Шегрена. Научно-практическая ревматология. 2002;40(1):13-16. doi: 10.14412/1995-4484-2002-742Shornikova NS, Vassiliev VI, Smirnov AV. Articular damage in Sjogren’s disease. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2002;40(1):13-16 (In Russ.). doi: 10.14412/1995-4484-2002-742Ballard M, Meyer O, Adle-Biassette H, Grossin M. Jaccoud’s arthropathy with vasculitis and primary Sjögren’s syndrome. A new entity. Clin Exp Rheumatol. 2006;24(2 Suppl 41):102-103.Ballard M, Meyer O, Adle-Biassette H, Grossin M. Jaccoud’s arthropathy with vasculitis and primary Sjögren’s syndrome. A new entity. Clin Exp Rheumatol. 2006;24(2 Suppl 41):102-103.Retamozo S, Brito-Zerón P, Ramos-Casals M. Prognostic markers of lymphoma development in primary Sjögren syndrome. Lupus. 2019;28(8):923-936. doi: 10.1177/0961203319857132Retamozo S, Brito-Zerón P, Ramos-Casals M. Prognostic markers of lymphoma development in primary Sjögren syndrome. Lupus. 2019;28(8):923-936. doi: 10.1177/0961203319857132Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-4038. doi: 10.1182/blood-2007-10-119974Ekström Smedby K, Vajdic CM, Falster M, Engels EA, MartínezMaza O, Turner J, et al. Autoimmune disorders and risk of nonHodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-4038. doi: 10.1182/blood-2007-10-119974Vasiliev V, Gorodetskiy V, Palshina S, Gaiduk I, Shornikova N, Сhaltsev B. Non-Hodgkin marginal cell lymphoma in patients with rheumatoid arthritis and Sjogren’s syndrome. Clinical and Experimental Rheumatology. 2022:43-44.Vasiliev V, Gorodetskiy V, Palshina S, Gaiduk I, Shornikova N, Сhaltsev B. Non-Hodgkin marginal cell lymphoma in patients with rheumatoid arthritis and Sjogren’s syndrome. Clinical and Experimental Rheumatology. 2022:43-44.Васильев ВИ, Чальцев БД, Городецкий ВР, Пальшина СГ, Шорникова НС, Ананьева ЛП, и др. Взаимосвязь болезни Шегрена, склеродермии и злокачественных онкогематологических заболеваний. Терапевтический архив. 2020;92(12):126- 136. doi: 10.26442/00403660.2020.12.200443Vasil’ev VI, Chal’tsev BD, Gorodetskii VR, Pal’shina SG, Shornikova NS, Anan’eva LP, et al. The relationship between Sjogren’s syndrome, systemic sclerosis and lymphoproliferative diseases. Terapevticheskii arkhiv. 2020;92(12):126-136 (In Russ.). doi: 10.26442/00403660.2020.12.200443Логвиненко ОА, Васильев ВИ, Ковригина АМ, Кокосадзе НВ, Гайдук ИВ, Митриков БВ, и др. Ритуксимаб в лечении нодальной В-клеточной лимфомы маргинальной зоны, болезни Шёгрена и аутоиммунного гепатита. Научно-практическая ревматология. 2008;46(5):64-71. doi: 10.14412/1995-4484-2008-417Logvinenko OA, Vasiljev VI, Kovrigina AM, Kokosadse NV, Gaiduk IV, Mitrikov BV, et al. Rituximab in the treatment of nodal B cell marginal zone lymphoma, primary Sjogren’s syndrome and autoimmune hepatitis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2008; 46(5):64-71 (In Russ.). doi: 10.14412/1995-4484-2008-417Andonopoulos AP, Drosos AA, Skopouli FN, Acritidis NC, Moutsopoulos HM. Secondary Sjögren’s syndrome in rheumatoid arthritis. J Rheumatol. 1987;14(6):1098-1103.Andonopoulos AP, Drosos AA, Skopouli FN, Acritidis NC, Moutsopoulos HM. Secondary Sjögren’s syndrome in rheumatoid arthritis. J Rheumatol. 1987;14(6):1098-1103.Andonopoulos AP, Drosos AA, Skopouli FN, Moutsopoulos HM. Sjögren’s syndrome in rheumatoid arthritis and progressive systemic sclerosis. A comparative study. Clin Exp Rheumatol. 1989;7(2):203-205.Andonopoulos AP, Drosos AA, Skopouli FN, Moutsopoulos HM. Sjögren’s syndrome in rheumatoid arthritis and progressive systemic sclerosis. A comparative study. Clin Exp Rheumatol. 1989;7(2):203-205.Brito-Zerón P, Retamozo S, Akasbi M, Gandía M, Perez-DeLis M, Soto-Cardenas MJ, et al. Annular erythema in primary Sjogren’s syndrome: Description of 43 non-Asian cases. Lupus. 2014;23(2):166-175. doi: 10.1177/0961203313515764Brito-Zerón P, Retamozo S, Akasbi M, Gandía M, Perez-DeLis M, Soto-Cardenas MJ, et al. Annular erythema in primary Sjogren’s syndrome: Description of 43 non-Asian cases. Lupus. 2014;23(2):166-175. doi: 10.1177/0961203313515764Alniemi DT, Gutierrez A Jr, Drage LA, Wetter DA. Subacute cutaneous lupus erythematosus: Clinical characteristics, disease associations, treatments, and outcomes in a series of 90 patients at Mayo clinic, 1996–2011. Mayo Clin Proc. 2017;92(3):406-414. doi: 10.1016/j.mayocp.2016.10.030Alniemi DT, Gutierrez A Jr, Drage LA, Wetter DA. Subacute cutaneous lupus erythematosus: Clinical characteristics, disease associations, treatments, and outcomes in a series of 90 patients at Mayo clinic, 1996–2011. Mayo Clin Proc. 2017;92(3):406-414. doi: 10.1016/j.mayocp.2016.10.030Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, Bowman SJ, Dörner T, et al.; EULAR Sjögren Syndrome Task Force. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford). 2015;54(12):2230-2238. doi: 10.1093/rheumatology/kev200Ramos-Casals M, Brito-Zerón P, Seror R, Bootsma H, Bowman SJ, Dörner T, et al.; EULAR Sjögren Syndrome Task Force. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford). 2015;54(12):2230-2238. doi: 10.1093/rheumatology/kev200Enomoto Y, Takemura T, Hagiwara E, Iwasawa T, Okudela K, Yanagawa N, et al. Features of usual interstitial pneumonia in patients with primary Sjögren’s syndrome compared with idiopathic pulmonary fibrosis. Respir Investig. 2014;52(4):227-235. doi: 10.1016/j.resinv.2014.02.003Enomoto Y, Takemura T, Hagiwara E, Iwasawa T, Okudela K, Yanagawa N, et al. Features of usual interstitial pneumonia in patients with primary Sjögren’s syndrome compared with idiopathic pulmonary fibrosis. Respir Investig. 2014;52(4):227-235. doi: 10.1016/j.resinv.2014.02.003Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, et al. Pulmonary manifestations of primary Sjogren’s syndrome: A clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005;171(6):632-638. doi: 10.1164/rccm.200403-417OCIto I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, et al. Pulmonary manifestations of primary Sjogren’s syndrome: A clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005;171(6):632-638. doi: 10.1164/rccm.200403-417OCWatanabe Y, Koyama S, Miwa C, Okuda S, Kanai Y, Tetsuka K, et al. Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in Sjögren’s syndrome showing only the LIP pattern radiologically. Intern Med. 2012;51(5):491-495. doi: 10.2169/internalmedicine.51.6242Watanabe Y, Koyama S, Miwa C, Okuda S, Kanai Y, Tetsuka K, et al. Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in Sjögren’s syndrome showing only the LIP pattern radiologically. Intern Med. 2012;51(5):491-495. doi: 10.2169/internalmedicine.51.6242Sirajuddin A, Raparia K, Lewis VA, Franks TJ, Dhand S, Galvin JR, et al. Primary pulmonary lymphoid lesions: Radiologic and pathologic findings. Radiographics. 2016;36(1):53-70. doi: 10.1148/rg.2016140339Sirajuddin A, Raparia K, Lewis VA, Franks TJ, Dhand S, Galvin JR, et al. Primary pulmonary lymphoid lesions: Radiologic and pathologic findings. Radiographics. 2016;36(1):53-70. doi: 10.1148/rg.2016140339Johkoh T, Müller NL, Pickford HA, Hartman TE, Ichikado K, Akira M, et al. Lymphocytic interstitial pneumonia: Thin-section CT findings in 22 patients. Radiology. 1999;212(2):567-572. doi: 10.1148/radiology.212.2.r99au05567Johkoh T, Müller NL, Pickford HA, Hartman TE, Ichikado K, Akira M, et al. Lymphocytic interstitial pneumonia: Thin-section CT findings in 22 patients. Radiology. 1999;212(2):567-572. doi: 10.1148/radiology.212.2.r99au05567Nicholson AG, Wotherspoon AC, Diss TC, Hansell DM, Du Bois R, Sheppard MN, et al. Reactive pulmonary lymphoid disorders. Histopathology. 1995;26(5):405-412. doi: 10.1111/j.1365-2559.1995.tb00247.xNicholson AG, Wotherspoon AC, Diss TC, Hansell DM, Du Bois R, Sheppard MN, et al. Reactive pulmonary lymphoid disorders. Histopathology. 1995;26(5):405-412. doi: 10.1111/j.1365-2559.1995.tb00247.xBrito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, et al.; EULAR-SS Task Force Big Data Consortium. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: A cross-sectional study from the Big Data Sjögren Project Consortium. Ann Rheum Dis. 2017;76(6):1042-1050. doi: 10.1136/annrheumdis-2016-209952Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, et al.; EULAR-SS Task Force Big Data Consortium. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: A cross-sectional study from the Big Data Sjögren Project Consortium. Ann Rheum Dis. 2017;76(6):1042-1050. doi: 10.1136/annrheumdis-2016-209952Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al.; EULAR Sjögren’s Task Force. EULAR Sjogren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103-1109. doi: 10.1136/ard.2009.110619Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al.; EULAR Sjögren’s Task Force. EULAR Sjogren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103-1109. doi: 10.1136/ard.2009.110619Васильев ВИ, Пробатова НА, Варламова ЕЮ, Тупицын НН, Симонова МВ, Сафонова ТН, и др. Прогностические последствия смешанной моноклональной криоглобулинемии при болезни Шегрена. Терапевтический архив. 2004;78(8):61- 68.Vasilyev VI, Probatova NA, Varlamova YY, Tupitsyn NN, Simonova MV, Safonova TN, et al. Prognostic implications of mixed monoclonal cryoglobulinemia in Sjogren’s disease. Terapevticheskii arkhiv. 2004;78(8):61-68 (In Russ.).Tsianos EB, Tzioufas AG, Kita MD, Tsolas O, Moutsopoulos HM. Serum isoamylases in patients with autoimmune rheumatic diseases. Clin Exp Rheumatol. 1984;2(3):235-238.Tsianos EB, Tzioufas AG, Kita MD, Tsolas O, Moutsopoulos HM. Serum isoamylases in patients with autoimmune rheumatic diseases. Clin Exp Rheumatol. 1984;2(3):235-238.Retamozo S, Acar-Denizli N, Rasmussen A, Horváth IF, Baldini C, Priori R, et al.; Sjögren Big Data Consortium. Systemic manifestations of primary Sjögren’s syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clin Exp Rheumatol. 2019;37 Suppl 118(3):97-106.Retamozo S, Acar-Denizli N, Rasmussen A, Horváth IF, Baldini C, Priori R, et al.; Sjögren Big Data Consortium. Systemic manifestations of primary Sjögren’s syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clin Exp Rheumatol. 2019;37 Suppl 118(3):97-106.Takagi Y, Hashimoto K, Sasaki M, Eida S, Katayama I, Sumi M. Juvenile onset of primary Sjögren’s syndrome: Changes in imaging findings during a 7-year progression. Clin Exp Rheumatol. 2022;40(12):2466-2467. doi: 10.55563/clinexprheumatol/z3exkqTakagi Y, Hashimoto K, Sasaki M, Eida S, Katayama I, Sumi M. Juvenile onset of primary Sjögren’s syndrome: Changes in imaging findings during a 7-year progression. Clin Exp Rheumatol. 2022;40(12):2466-2467. doi: 10.55563/clinexprheumatol/z3exkqLam R, Muniraj T. Hyperamylasemia.. In: Treasure Island (FL):StatPearls Publishing;2024. URL: https://www.ncbi.nlm.nih.gov/books/NBK559273/ (Accessed: 25 December 2024).Lam R, Muniraj T. Hyperamylasemia.. In: Treasure Island (FL):StatPearls Publishing;2024. URL: https://www.ncbi.nlm.nih.gov/books/NBK559273/ (Accessed: 25 December 2024).Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518- 2534. doi: 10.1093/brain/awh605Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518- 2534. doi: 10.1093/brain/awh605Gorson KC, Ropper AH. Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: Clinical implications. Muscle Nerve. 2003;28(5):553-560. doi: 10.1002/mus.10470Gorson KC, Ropper AH. Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: Clinical implications. Muscle Nerve. 2003;28(5):553-560. doi: 10.1002/mus.10470Gøransson LG, Herigstad A, Tjensvoll AB, Harboe E, Mellgren SI, Omdal R. Peripheral neuropathy in primary Sjogren syndrome: A population-based study. Arch Neurol. 2006;63(11):1612- 1615. doi: 10.1001/archneur.63.11.1612Gøransson LG, Herigstad A, Tjensvoll AB, Harboe E, Mellgren SI, Omdal R. Peripheral neuropathy in primary Sjogren syndrome: A population-based study. Arch Neurol. 2006;63(11):1612- 1615. doi: 10.1001/archneur.63.11.1612Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, et al. Refining myositis associated with primary Sjögren’s syndrome: Data from the prospective cohort ASSESS. Rheumatology (Oxford). 2021;60(2):675-681. doi: 10.1093/rheumatology/keaa257Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, et al. Refining myositis associated with primary Sjögren’s syndrome: Data from the prospective cohort ASSESS. Rheumatology (Oxford). 2021;60(2):675-681. doi: 10.1093/rheumatology/keaa257Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford). 2022;61(5):2016-2024. doi: 10.1093/rheumatology/keab716Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford). 2022;61(5):2016-2024. doi: 10.1093/rheumatology/keab716Хван ЮИ, Хелковская-Сергеева АН. Сочетание спорадического миозита с включениями и болезни Шегрена: обзор литературы и описание случая. Современная ревматология. 2023;17(1):78-82. doi: 10.14412/1996-7012-2023-1-78-82Khvan YI, Khelkovskaya-Sergeeva AN. Combination of sporadic inclusion body myositis and primary Sjögren’s syndrome: Clinical case and review of literature. Modern Rheumatology Journal. 2023;17(1):78-82 (In Russ.). doi: 10.14412/1996-7012-2023-1-78-82Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjögren’s syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore). 1992;71(6):386-403.Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjögren’s syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore). 1992;71(6):386-403.Pereira FG, Nogueira R, Pataca I, Sampaio R. Chronic sclerosing sialadenitis (Küttner’s tumour) of the submandibular gland: A neoplastic mimic. BMJ Case Rep. 2022;15(1):e245518. doi: 10.1136/bcr-2021-245518Pereira FG, Nogueira R, Pataca I, Sampaio R. Chronic sclerosing sialadenitis (Küttner’s tumour) of the submandibular gland: A neoplastic mimic. BMJ Case Rep. 2022;15(1):e245518. doi: 10.1136/bcr-2021-245518Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive review of AL amyloidosis: Some practical recommendations. Blood Cancer J. 2021;11(5):97. doi: 10.1038/s41408-021-00486-4Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive review of AL amyloidosis: Some practical recommendations. Blood Cancer J. 2021;11(5):97. doi: 10.1038/s41408-021-00486-4Araújo GR, Morais-Perdigão AL, Lopez-de-Cáceres CV, Almeida OP, Vargas PA, Roman-Tager EM, et al. Lymphomas affecting the submandibular glands. Med Oral Patol Oral Cir Bucal. 2024;29(1):e78-e86. doi: 10.4317/medoral.26065Araújo GR, Morais-Perdigão AL, Lopez-de-Cáceres CV, Almeida OP, Vargas PA, Roman-Tager EM, et al. Lymphomas affecting the submandibular glands. Med Oral Patol Oral Cir Bucal. 2024;29(1):e78-e86. doi: 10.4317/medoral.26065Васильев ВИ, Гайдук ИВ, Пальшина СГ, Городецкий ВР, Сокол ЕВ, Родионова ЕБ, и др. Первичные онкогематологические заболевания, дебютирующие с поражения больших слюнных желез в ревматологической практике. Современная ревматология. 2019;13(1):44-51. doi: 10.14412/1996-7012-2019-1-44-51Vasilyev VI, Gaiduk IV, Palshina SG, Gorodetsky VR, Sokol EV, Rodionova EB, et al. Primary hematologic malignancies with the onset of involvement of the major salivary glands in rheumatologic practice. Modern Rheumatology Journal. 2019;13(1):44-51 (In Russ.). doi: 10.14412/1996-7012-2019-1-44-51Васильев ВИ, Сокол ЕВ, Родионова ЕБ, Пальшина СГ, Александрова ЕН, Раденска-Лоповок СГ, и др. Связанные с IgG-4 поражения слюнных желез. Терапевтический архив. 2015;87(8):92-102. doi: 10.17116/terarkh201587892-102Vasilyev VI, Sokol EV, Rodionova EB, Palshina SG, Aleksandrova EN, Radenska-Lopovok SG, et al. IgG4- related salivary gland lesions. Terapevticheskii arkhiv. 2015;87(8):92-102 (In Russ.). doi: 10.17116/terarkh201587892-102Васильев ВИ, Пробатова НА, Тупицын НН, Варламова ЕЮ, Логвиненко ОА, Ковригина АМ, и др. Лимфопролиферативные заболевания при болезни Шегрена. Онкогематология. 2007;2(3):16-26. doi: 10.17650/1818-8346-2007-0-3-16-26Vasiljev VI, Probatova NA, Tupitsyn NN, Varlamova EY, Logvinenko OA, Kovrigina AM, et al. Lymphoproliferative diseases in primary Sjogren’s syndrome. Oncohematology. 2007; 2(3):16-26 (In Russ.). doi: 10.17650/1818-8346-2007-0-3-16-26Васильев ВИ, Логвиненко ОА, Пробатова НА, Кокосадзе НВ, Городецкий ВР, Ковригина АМ, и др. Роль биопсии околоушной слюнной железы в ранней диагностике лимфом при болезни Шегрена. Терапевтический архив. 2009;81(6):20- 26.Vasil’ev VI, Logvinenko OA, Probatova NA, Kokosadze NV, Gorodetskiy VR, Kovrigina AM, et al. The role of parotid gland biopsy in early detection of lymphoma in primary Sjogren’s syndrome. Terapevticheskii arkhiv. 2009;81(6):20-26 (In Russ.).García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270-280. doi: 10.1097/00005792-200207000-00003García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, CalvoAlen J, Cervera R, et al. Primary Sjögren syndrome: Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270-280. doi: 10.1097/00005792-200207000-00003Chatzis LG, Stergiou IE, Goules AV, Pezoulas V, Tsourouflis G, Fotiadis D, et al. Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren’s syndrome: Results from a harmonized dataset (1981–2021). Rheumatology (Oxford). 2022;61(9):3576-3585. doi: 10.1093/rheumatology/keab939Chatzis LG, Stergiou IE, Goules AV, Pezoulas V, Tsourouflis G, Fotiadis D, et al. Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren’s syndrome: Results from a harmonized dataset (1981–2021). Rheumatology (Oxford). 2022;61(9):3576-3585. doi: 10.1093/rheumatology/keab939Hernández-Molina G, Kostov B, Brito-Zerón P, Vissink A, Mandl T, Hinrichs AC, et al.; Sjögren Big Data Consortium. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology (Oxford). 2022;62(1):243-255. doi: 10.1093/rheumatology/keac205Hernández-Molina G, Kostov B, Brito-Zerón P, Vissink A, Mandl T, Hinrichs AC, et al.; Sjögren Big Data Consortium. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology (Oxford). 2022;62(1):243-255. doi: 10.1093/rheumatology/keac205Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren’s syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum. 1999;42(8):1765-1772. doi: 10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-VVoulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren’s syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum. 1999;42(8):1765-1772. doi: 10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-VGorodetskiy VR, Probatova NA, Radenska-Lopovok SG, Ryzhikova NV, Sidorova YV, Sudarikov AB. Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren’s syndrome patients: Case series study and review of the literature. Rheumatol Int. 2020;40(3):499-506. doi: 10.1007/s00296-019-04470-xGorodetskiy VR, Probatova NA, Radenska-Lopovok SG, Ryzhikova NV, Sidorova YV, Sudarikov AB. Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren’s syndrome patients: Case series study and review of the literature. Rheumatol Int. 2020;40(3):499-506. doi: 10.1007/s00296-019-04470-xNocturne G, Mariette X. Sjögren syndrome-associated lymphomas: An update on pathogenesis and management. Br J Haematol. 2015;168(3):317-327. doi: 10.1111/bjh.13192Nocturne G, Mariette X. Sjögren syndrome-associated lymphomas: An update on pathogenesis and management. Br J Haematol. 2015;168(3):317-327. doi: 10.1111/bjh.13192Alunno A, Leone MC, Giacomelli R, Gerli R, Carubbi F. Lymphoma and lymphomagenesis in primary Sjögren’s syndrome. Front Med (Lausanne). 2018;5:102. doi: 10.3389/fmed.2018.00102Alunno A, Leone MC, Giacomelli R, Gerli R, Carubbi F. Lymphoma and lymphomagenesis in primary Sjögren’s syndrome. Front Med (Lausanne). 2018;5:102. doi: 10.3389/fmed.2018.00102Teixeira Mendes LS, Wotherspoon A. Marginal zone lymphoma: Associated autoimmunity and auto-immune disorders. Best Pract Res Clin Haematol. 2017;30(1-2):65-76. doi: 10.1016/j.beha.2016.07.006Teixeira Mendes LS, Wotherspoon A. Marginal zone lymphoma: Associated autoimmunity and auto-immune disorders. Best Pract Res Clin Haematol. 2017;30(1-2):65-76. doi: 10.1016/j.beha.2016.07.006Васильев ВИ, Городецкий ВР, Чальцев БД, Пробатова НA, Шорникова НС, Кокосадзе НВ, и др. Трансформированный вариант диффузной В-клеточной крупноклеточной лимфомы желудка у пациентки с сочетанием болезни Шегрена и системной склеродермии (описание случая и обзор литературы). Современная ревматология. 2022;16(6):84- 91. doi: 10.14412/1996-7012-2022-6-84-91Vasiliev VI, Gorodetskiy VR, Chaltsev BD, Probatova NA, Shornikova NS, Kokosadze NV, et al. Transformed diffuse large B-cell lymphoma of the stomach in a patient with Sjögren’s disease and systemic sclerosis: Case report and literature review. Modern Rheumatology Journal. 2022;16(6):84 91 (In Russ.). doi: 10.14412/1996-7012-2022-6-84-91Gorodetskiy VR, Probatova NA, Vasilyev VI. Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren’s syndrome. Int J Rheum Dis. 2020;23(4):540-548. doi: 10.1111/1756-185X.13800Gorodetskiy VR, Probatova NA, Vasilyev VI. Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren’s syndrome. Int J Rheum Dis. 2020;23(4):540-548. doi: 10.1111/1756-185X.13800De Vita S, Isola M, Baldini C, Goules AV, Chatzis LG, et al. Predicting lymphoma in Sjögren’s syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording. Rheumatology (Oxford). 2023;62(4):1586-1593. doi:10.1093/rheumatology/keac470De Vita S, Isola M, Baldini C, Goules AV, Chatzis LG, et al. Predicting lymphoma in Sjögren’s syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording. Rheumatology (Oxford). 2023;62(4):1586-1593. doi:10.1093/rheumatology/keac470Baldini C, Mosca M, Della Rossa A, Pepe P, Notarstefano C, Ferro F, et al. Overlap of ACA-positive systemic sclerosis and Sjögren’s syndrome: A distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol. 2013;31(2):272-280.Baldini C, Mosca M, Della Rossa A, Pepe P, Notarstefano C, Ferro F, et al. Overlap of ACA-positive systemic sclerosis and Sjögren’s syndrome: A distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol. 2013;31(2):272-280.Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, et al.; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18. doi: 10.1136/annrheumdis-2019-216114Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, et al.; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18. doi: 10.1136/annrheumdis-2019-216114Price EJ, Benjamin S, Bombardieri M, Bowman S, Carty S, Ciurtin C, et al. British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Rheumatology (Oxford). 2025;64(2):409-439. doi: 10.1093/rheumatology/keae152Price EJ, Benjamin S, Bombardieri M, Bowman S, Carty S, Ciurtin C, et al. British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Rheumatology (Oxford). 2025;64(2):409-439. doi: 10.1093/rheumatology/keae152Chaltsev B. The course of primary Sjogren’s syndrome prior to the development of lymphoma: Should systemic therapy be used in the treatment of glandular forms of the disease? Clinical and Experimental Rheumatology. 2022:41.Chaltsev B. The course of primary Sjogren’s syndrome prior to the development of lymphoma: Should systemic therapy be used in the treatment of glandular forms of the disease? Clinical and Experimental Rheumatology. 2022:41.Flores-Chávez A, Kostov B, Solans R, Fraile G, Maure B, Feijoo-Massó C, et al.; GEAS-SS SEMI Registry. Severe, life-threatening phenotype of primary Sjögren’s syndrome: Clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018;36 Suppl 112(3):121-129.Flores-Chávez A, Kostov B, Solans R, Fraile G, Maure B, FeijooMassó C, et al.; GEAS-SS SEMI Registry. Severe, life-threatening phenotype of primary Sjögren’s syndrome: Clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018;36 Suppl 112(3):121-129.Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary Sjögren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford). 2005;44(4):449-455. doi: 10.1093/rheumatology/keh506Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary Sjögren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford). 2005;44(4):449-455. doi: 10.1093/rheumatology/keh506Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren’s syndrome: Its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58(4):253- 256. doi: 10.1136/ard.58.4.25Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren’s syndrome: Its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58(4):253- 256. doi: 10.1136/ard.58.4.25Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: The JOQUER randomized clinical trial. JAMA. 2014;312(3):249-258. doi: 10.1001/jama.2014.7682Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: The JOQUER randomized clinical trial. JAMA. 2014;312(3):249-258. doi: 10.1001/jama.2014.7682Kruize AA, Hené RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjögren’s syndrome: A two year double blind crossover trial. Ann Rheum Dis. 1993;52(5):360-364. doi: 10.1136/ard.52.5.360Kruize AA, Hené RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjögren’s syndrome: A two year double blind crossover trial. Ann Rheum Dis. 1993;52(5):360-364. doi: 10.1136/ard.52.5.360Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren’s syndrome. Nat Clin Pract Rheumatol. 2006;2(5):252-261. doi: 10.1038/ncprheum0165Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren’s syndrome. Nat Clin Pract Rheumatol. 2006;2(5):252-261. doi: 10.1038/ncprheum0165Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren’s syndrome. Clin Exp Rheumatol. 1996;14(5):555-558.Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjögren’s syndrome. Clin Exp Rheumatol. 1996;14(5):555-558.Городецкий ВР, Пробатова НА, Логвиненко ОА, Васильев ВИ, Огородникова МД Седышев СХ, и др. Ревматоидный артрит с синдромом Шегрена и MALT-лимфомой околоушной железы, сочетающийся с множественной миеломой: описание случая и обзор литературы. Научно-практическая ревматология. 2010;48(2):103-106. doi: 10.14412/1995-4484-2010-1423Gorodetsky VR, Probatova NA, Logvinenko OA, Vasil’ev VI, Ogorodnikova MD, Sedyshev SKh, et al. Rheumatoid arthritis with Sjogren’s syndrome and MALT lymphoma of the parotid gland, associatedwith multiple myeloma: Description of a case and review of literature. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2010;48(2):103-106 (In Russ.). doi: 10.14412/1995-4484-2010-1423Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren’s syndrome: Case series. J Rheumatol. 2001;28(1):47-53.Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren’s syndrome: Case series. J Rheumatol. 2001;28(1):47-53.Sutcliffe N, Smith C, Speight PM, Isenberg DA. Mucosa-associated lymphoid tissue lymphomas in two patients with rheumatoid arthritis on second-line agents, and secondary Sjögren’s syndrome. Rheumatology (Oxford). 2000;39(2):185-188. doi: 10.1093/rheumatology/39.2.185Sutcliffe N, Smith C, Speight PM, Isenberg DA. Mucosa-associated lymphoid tissue lymphomas in two patients with rheumatoid arthritis on second-line agents, and secondary Sjögren’s syndrome. Rheumatology (Oxford). 2000;39(2):185-188. doi: 10.1093/rheumatology/39.2.185Chaltsev B, Vasiliev V, Palshina S, Torgashina A, Sokol E, Khvan Y. Lymphomas in patients with rheumatoid arthritis. Int J Rheum Dis. 2021;24:221. doi: 10.1111/1756-185X.14200Chaltsev B, Vasiliev V, Palshina S, Torgashina A, Sokol E, Khvan Y. Lymphomas in patients with rheumatoid arthritis. Int J Rheum Dis. 2021;24:221. doi: 10.1111/1756-185X.14200Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi: 10.1136/ard-2022-223356Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi: 10.1136/ard-2022-223356Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi: 10.1002/acr.24596Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi: 10.1002/acr.24596Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al.; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al.; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: Results of the randomized, controlled trial of Remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270- 1276. doi: 10.1002/art.20146Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren’s syndrome: Results of the randomized, controlled trial of Remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270- 1276. doi: 10.1002/art.20146Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren’s syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50(7):2240-2245. doi: 10.1002/art.20299Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren’s syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50(7):2240-2245. doi: 10.1002/art.20299Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjögren’s syndrome: A pilot study. J Rheumatol. 2004;31(1):96-101.Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjögren’s syndrome: A pilot study. J Rheumatol. 2004;31(1):96-101.Felten R, Devauchelle-Pensec V, Seror R, Duffau P, Saadoun D, Hachulla E, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: A multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2021;80(3):329-338. doi: 10.1136/annrheumdis-2020-218467Felten R, Devauchelle-Pensec V, Seror R, Duffau P, Saadoun D, Hachulla E, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: A multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2021;80(3):329-338. doi: 10.1136/annrheumdis-2020-218467Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, et al. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: A randomized, phase 2, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022;61(12):4797-4808. doi: 10.1093/rheumatology/keac167Price E, Bombardieri M, Kivitz A, Matzkies F, Gurtovaya O, Pechonkina A, et al. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: A randomized, phase 2, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022;61(12):4797-4808. doi: 10.1093/rheumatology/keac167Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, et al. Efficacy and safety of abatacept in active primary Sjögren’s syndrome: Results of a phase III, randomised, placebocontrolled trial. Ann Rheum Dis. 2021;80(3):339-348. doi: 10.1136/annrheumdis-2020-218599Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, et al. Efficacy and safety of abatacept in active primary Sjögren’s syndrome: Results of a phase III, randomised, placebocontrolled trial. Ann Rheum Dis. 2021;80(3):339-348. doi: 10.1136/annrheumdis-2020-218599Calip GS, Patel PR, Adimadhyam S, Xing S, Wu Z, Sweiss K, et al. Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer. 2018;143(5):1062-1071. doi: 10.1002/ijc.31407Calip GS, Patel PR, Adimadhyam S, Xing S, Wu Z, Sweiss K, et al. Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer. 2018;143(5):1062-1071. doi: 10.1002/ijc.31407Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740-1751. doi: 10.1002/art.20311Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740-1751. doi: 10.1002/art.20311Tanaka K, Ichikawa A, Umezawa N, Yamamoto K, Yoshifuji K, Okada K, et al. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci. 2023;114(9):3719-3727. doi: 10.1111/cas.15894Tanaka K, Ichikawa A, Umezawa N, Yamamoto K, Yoshifuji K, Okada K, et al. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci. 2023;114(9):3719-3727. doi: 10.1111/cas.15894Gong S, Crane GM, McCall CM, Xiao W, Ganapathi KA, Cuka N, et al. Expanding the spectrum of EBV-positive marginal zone lymphomas: A lesion associated with diverse immunodeficiency settings. Am J Surg Pathol. 2018;42(10):1306-1316. doi: 10.1097/PAS.0000000000001113Gong S, Crane GM, McCall CM, Xiao W, Ganapathi KA, Cuka N, et al. Expanding the spectrum of EBV-positive marginal zone lymphomas: A lesion associated with diverse immunodeficiency settings. Am J Surg Pathol. 2018;42(10):1306-1316. doi: 10.1097/PAS.0000000000001113Vasiliev V, Palshina S, Gaiduc I, Probatova N, Gorodetskiy V, Chaltsev B. Marginal zone lymphomas in primary and secondary Sjogren’s syndrome. Clinical and Experimental Rheumatology. 2022:41-42.Vasiliev V, Palshina S, Gaiduc I, Probatova N, Gorodetskiy V, Chaltsev B. Marginal zone lymphomas in primary and secondary Sjogren’s syndrome. Clinical and Experimental Rheumatology. 2022:41-42.Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: A randomized trial. Ann Intern Med. 2014;160(4):233-242. doi: 10.7326/M13-1085Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: A randomized trial. Ann Intern Med. 2014;160(4):233-242. doi: 10.7326/M13-1085Bowman SJ, Everett CC, O’Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol. 2017;69(7):1440-1450. doi: 10.1002/art.40093Bowman SJ, Everett CC, O’Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol. 2017;69(7):1440-1450. doi: 10.1002/art.40093Cornec D, Costa S, Devauchelle-Pensec V, Jousse-Joulin S, Marcorelles P, Berthelot JM, et al. Blood and salivary-gland BAFFdriven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren’s syndrome. J Autoimmun. 2016;67:102-110. doi: 10.1016/j.jaut.2015.11.002Cornec D, Costa S, Devauchelle-Pensec V, Jousse-Joulin S, Marcorelles P, Berthelot JM, et al. Blood and salivary-gland BAFFdriven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren’s syndrome. J Autoimmun. 2016;67:102-110. doi: 10.1016/j.jaut.2015.11.002Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum. 2007;56(5):1464-77. doi: 10.1002/art.22603Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum. 2007;56(5):1464-77. doi: 10.1002/art.22603Haacke EA, Bootsma H, Spijkervet FKL, Visser A, Vissink A, Kluin PM, et al. FcRL4+ B-cells in salivary glands of primary Sjögren’s syndrome patients. J Autoimmun. 2017;81:90-98. doi: 10.1016/j.jaut.2017.03.012Haacke EA, Bootsma H, Spijkervet FKL, Visser A, Vissink A, Kluin PM, et al. FcRL4+ B-cells in salivary glands of primary Sjögren’s syndrome patients. J Autoimmun. 2017;81:90-98. doi: 10.1016/j.jaut.2017.03.012Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: A prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15(5):R172. doi: 10.1186/ar4359Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: A prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15(5):R172. doi: 10.1186/ar4359Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1- 40. doi: 10.14412/1995-4484-2019-3-40Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.). doi: 10.14412/1995-4484-2019-3-40Торгашина АВ. Эффективность ритуксимаба при железистых формах болезни Шёгрена по результатам международных клинических исследований. Современная ревматология. 2020;14(1):85-92. doi: 10.14412/1996-7012-2020-1-85-92Torgashina AV. Efficacy of rituximab for glandular Sjögren’s disease according to international clinical trials. Modern Rheumatology Journal. 2020;14(1):85-92 (In Russ.). doi: 10.14412/1996-7012-2020-1-85-92Pontarini E, Sciacca E, Chowdhury F, Grigoriadou S, Rivellese F, Murray-Brown WJ, et al.; Trial for Anti-B Cell Therapy in Patients with Primary Sjögren Syndrome Study Research Group. Serum and tissue biomarkers associated with Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B cell-targeted therapy in the TRIAL of Anti-B Cell Therapy in Patients with Primary Sjögren Syndrome (TRACTISS). Arthritis Rheumatol. 2024;76(5):763-776. doi: 10.1002/art.42772Pontarini E, Sciacca E, Chowdhury F, Grigoriadou S, Rivellese F, Murray-Brown WJ, et al.; Trial for Anti-B Cell Therapy in Patients with Primary Sjögren Syndrome Study Research Group. Serum and tissue biomarkers associated with Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B cell-targeted therapy in the TRIAL of Anti-B Cell Therapy in Patients with Primary Sjögren Syndrome (TRACTISS). Arthritis Rheumatol. 2024;76(5):763-776. doi: 10.1002/art.42772Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017.Nasonov EL (ed.). Rheumatology. Russian clinical recommendations. Moscow:GEOTAR-Media;2017 (In Russ.).Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, et al. Treatment guidelines for rheumatologic manifestations of Sjögren’s syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken). 2017;69(4):517-527. doi: 10.1002/acr.22968Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, et al. Treatment guidelines for rheumatologic manifestations of Sjögren’s syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken). 2017;69(4):517-527. doi: 10.1002/acr.22968Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, et al. Clinical practice guideline for Sjögren’s syndrome 2017. Mod Rheumatol. 2018;28(3):383-408. doi: 10.1080/14397595.2018.1438093Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, et al. Clinical practice guideline for Sjögren’s syndrome 2017. Mod Rheumatol. 2018;28(3):383-408. doi: 10.1080/14397595.2018.1438093Almeida D, Vianna K, Arriaga P, Moraschini V. Dental implants in Sjögren’s syndrome patients: A systematic review. PLoS One. 2017;12(12):e0189507. doi: 10.1371/journal.pone.0189507Almeida D, Vianna K, Arriaga P, Moraschini V. Dental implants in Sjögren’s syndrome patients: A systematic review. PLoS One. 2017;12(12):e0189507. doi: 10.1371/journal.pone.0189507Maarse F, Fennis WMM, Twisk JWR, Korfage A, Santing HJ, den Hartog L, et al. Dental implants in dentate primary and secondary Sjögren’s syndrome patients: A multicenter prospective cohort study. Clin Oral Implants Res. 2022;33(11):1157-1170. doi: 10.1111/clr.13998Maarse F, Fennis WMM, Twisk JWR, Korfage A, Santing HJ, den Hartog L, et al. Dental implants in dentate primary and secondary Sjögren’s syndrome patients: A multicenter prospective cohort study. Clin Oral Implants Res. 2022;33(11):1157-1170. doi: 10.1111/clr.13998García-Marqués JV, Talens-Estarelles C, García-Lázaro S, Wolffsohn JS, Cerviño A. Systemic, environmental and lifestyle risk factors for dry eye disease in a mediterranean Caucasian population. Cont Lens Anterior Eye. 2022;45(5):101539. doi: 10.1016/j.clae.2021.101539García-Marqués JV, Talens-Estarelles C, García-Lázaro S, Wolffsohn JS, Cerviño A. Systemic, environmental and lifestyle risk factors for dry eye disease in a mediterranean Caucasian population. Cont Lens Anterior Eye. 2022;45(5):101539. doi: 10.1016/j.clae.2021.101539Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015;13(2):118-132. doi: 10.1016/j.jtos.2014.12.001Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015;13(2):118-132. doi: 10.1016/j.jtos.2014.12.001

The authors declare that there are no conflicts of interest present.